Mesenchymal stem cells (MSCs) have an ability to direct the healing process in the face of injury, insult and inflammation. This ability to direct is performed via the secretion of bioactives. Found throughout the body, MSCs are mostly attached to blood vessels of which, fat tissue (adipose) is a plentiful and rich source. From a therapeutic perspective, MSCs have been utilised from self (autologous) and from non-self (allogeneic) for a range of inflammatory and autoimmune conditions. MSCs have the capability to differentiate into specialised cell types like bone, cartilage and muscle to assist with regeneration and repair.
We have entered into a strategic collaboration and licensing agreement with AGC Asahi-Glass (AGC) a world leading manufacturer of glass, chemicals, high-tech materials and biopharmaceuticals, for the manufacture, clinical development and commercialisation for Progenza for the Japanese market.
We have partnered with a leading animal pharmaceutical company for canine CryoShot, our cell therapy technology for the treatment of osteoarthritis and other musculoskeletal disorders.